Global Peripheral Vascular Disease (PVD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

August 2019 •
130 pages •
Report ID: 5811446 •
Format: PDF

Summary
Table of contents

High levels of pipeline activity are being observed in Peripheral Vascular Disease (PVD) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including 480 Biomedical Inc, Alucent Medical Inc, Anaeropharma Science Inc, AnGes MG Inc, AngioSoma Inc and others.

A Significant contribution to the Peripheral Vascular Disease (PVD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Vascular Disease (PVD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Peripheral Vascular Disease (PVD) condition and increased access to investments is encouraging growth of Peripheral Vascular Disease (PVD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Peripheral Vascular Disease (PVD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Peripheral Vascular Disease (PVD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Peripheral Vascular Disease (PVD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Vascular Disease (PVD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Vascular Disease (PVD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Vascular Disease (PVD) pipeline and formulate effective research and development strategies.

Research Methodology
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Peripheral Vascular Disease (PVD) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Peripheral Vascular Disease (PVD) drugs
- Late phase: Phase 3 and in-approval Peripheral Vascular Disease (PVD) drugs

Companies involved in the Pipeline-
- Company overview
- Snapshot
- Peripheral Vascular Disease (PVD) therapeutic treatment activities

Details for each Peripheral Vascular Disease (PVD) drug candidate-
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details

Other details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate

Recent Peripheral Vascular Disease (PVD) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager